Influence of HII01 Supplementation on Glycemia and Inflammatory Biomarkers in Type 2 Diabetes: A Randomized Clinical Trial

Overview

Journal Foods

Specialty Biotechnology

Date 2021 Jul 2

PMID 34201653

Citations 26

Authors

Parichart Toejing

Nanticha Khampithum

Sasithorn Sirilun

Chaiyavat Chaiyasut

Narissara Lailerd

Affiliations

Soon will be listed here.

Abstract

It has been shown that gut dysbiosis can be associated with the development of type 2 diabetes mellitus (T2DM). Consequently, intervention with probiotics may be a useful approach to improve metabolic variables in diabetes. The present study aimed to evaluate the efficacy of HII01 on glycemia in T2DM patients. In a randomized, double-blind, placebo-controlled study, 50 participants were allocated to receive HII01 (50 × 10 CFU/day) or a placebo (corn starch 10 mg/day). Blood and fecal samples were assessed at baseline and at the end of the trial. After 12 weeks of intervention, fasting blood glucose level had significantly decreased in the probiotic group compared with the placebo group. Importantly, probiotic supplementation significantly decreased the plasma levels of LPS, TNF-α, IL-6 and hsCRP compared the placebo group. Additionally, an increase in beneficial bacteria and a decrease in pathogenic bacteria, which related to the improvement of SCFAs, was found following HII01 supplementation. These findings demonstrated that HII01 improved hyperglycemia and inflammatory markers by favorably modifying gut microbiota and subsequently ameliorating the leaky gut and endotoxemia, thereby suggesting a potential role as an adjuvant treatment in type 2 diabetes.

Citing Articles

Multistrain Probiotics and Telomere Length in Type 2 Diabetes: A 24-Week Randomized Controlled Trial.

Chaithanya V, Kumar J, Leela K, Baig H, Soliman M, Alenezy A Life (Basel). 2025; 15(2).

PMID: 40003720 PMC: 11856756. DOI: 10.3390/life15020311.

Health-Promoting and Functional Properties of Fermented Milk Beverages with Probiotic Bacteria in the Prevention of Civilization Diseases.

Stachelska M, Karpinski P, Kruszewski B Nutrients. 2025; 17(1.

PMID: 39796443 PMC: 11722897. DOI: 10.3390/nu17010009.

Low-Molecular-Weight Compounds Produced by the Intestinal Microbiota and Cardiovascular Disease.

Cuervo L, McAlpine P, Olano C, Fernandez J, Lombo F Int J Mol Sci. 2024; 25(19).

PMID: 39408727 PMC: 11477366. DOI: 10.3390/ijms251910397.

Modulatory Effects of Isolated Lactobacillus paracasei from Malaysian Water Kefir Grains on the Intestinal Barrier and Gut Microbiota in Diabetic Mice.

Talib N, Mohamad N, Ho C, Masarudin M, Alitheen N Probiotics Antimicrob Proteins. 2024; .

PMID: 39313703 DOI: 10.1007/s12602-024-10367-4.

The Role and Mechanism of Probiotics Supplementation in Blood Glucose Regulation: A Review.

Shen X, Ma C, Yang Y, Liu X, Wang B, Wang Y Foods. 2024; 13(17).

PMID: 39272484 PMC: 11394447. DOI: 10.3390/foods13172719.

References

Netto Candido T, Bressan J, de Cassia Goncalves Alfenas R . Dysbiosis and metabolic endotoxemia induced by high-fat diet. Nutr Hosp. 2018; 35(6):1432-1440. DOI: 10.20960/nh.1792. View

Wen L, Duffy A . Factors Influencing the Gut Microbiota, Inflammation, and Type 2 Diabetes. J Nutr. 2017; 147(7):1468S-1475S. PMC: 5483960. DOI: 10.3945/jn.116.240754. View

Cani P, Bibiloni R, Knauf C, Waget A, Neyrinck A, Delzenne N . Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008; 57(6):1470-81. DOI: 10.2337/db07-1403. View

Ejtahed H, Mohtadi-Nia J, Homayouni-Rad A, Niafar M, Asghari-Jafarabadi M, Mofid V . Probiotic yogurt improves antioxidant status in type 2 diabetic patients. Nutrition. 2011; 28(5):539-43. DOI: 10.1016/j.nut.2011.08.013. View

Khalili L, Alipour B, Asghari Jafar-Abadi M, Faraji I, Hassanalilou T, Mesgari Abbasi M . The Effects of Lactobacillus casei on Glycemic Response, Serum Sirtuin1 and Fetuin-A Levels in Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial. Iran Biomed J. 2018; 23(1):68-77. PMC: 6305821. View

Fuke N, Nagata N, Suganuma H, Ota T . Regulation of Gut Microbiota and Metabolic Endotoxemia with Dietary Factors. Nutrients. 2019; 11(10). PMC: 6835897. DOI: 10.3390/nu11102277. View

Hill C, Guarner F, Reid G, Gibson G, Merenstein D, Pot B . Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014; 11(8):506-14. DOI: 10.1038/nrgastro.2014.66. View

Plaza-Diaz J, Ruiz-Ojeda F, Gil-Campos M, Gil A . Mechanisms of Action of Probiotics. Adv Nutr. 2019; 10(suppl_1):S49-S66. PMC: 6363529. DOI: 10.1093/advances/nmy063. View

Xu J, Liang R, Zhang W, Tian K, Li J, Chen X . Faecalibacterium prausnitzii-derived microbial anti-inflammatory molecule regulates intestinal integrity in diabetes mellitus mice via modulating tight junction protein expression. J Diabetes. 2019; 12(3):224-236. PMC: 7064962. DOI: 10.1111/1753-0407.12986. View

10.

Kim C . Microbiota or short-chain fatty acids: which regulates diabetes?. Cell Mol Immunol. 2017; 15(2):88-91. PMC: 5811682. DOI: 10.1038/cmi.2017.57. View

11.

Zhang X, Shen D, Fang Z, Jie Z, Qiu X, Zhang C . Human gut microbiota changes reveal the progression of glucose intolerance. PLoS One. 2013; 8(8):e71108. PMC: 3754967. DOI: 10.1371/journal.pone.0071108. View

12.

Karczewski J, Troost F, Konings I, Dekker J, Kleerebezem M, Brummer R . Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastrointest Liver Physiol. 2010; 298(6):G851-9. DOI: 10.1152/ajpgi.00327.2009. View

13.

Bodera P, Chcialowski A . Immunomodulatory effect of probiotic bacteria. Recent Pat Inflamm Allergy Drug Discov. 2009; 3(1):58-64. DOI: 10.2174/187221309787158461. View

14.

Ley R, Turnbaugh P, Klein S, Gordon J . Microbial ecology: human gut microbes associated with obesity. Nature. 2006; 444(7122):1022-3. DOI: 10.1038/4441022a. View

15.

Saeedi P, Petersohn I, Salpea P, Malanda B, Karuranga S, Unwin N . Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas, 9 edition. Diabetes Res Clin Pract. 2019; 157:107843. DOI: 10.1016/j.diabres.2019.107843. View

16.

Eliakim-Raz N, Fishman G, Yahav D, Goldberg E, Stein G, Zvi H . Predicting Clostridium difficile infection in diabetic patients and the effect of metformin therapy: a retrospective, case-control study. Eur J Clin Microbiol Infect Dis. 2015; 34(6):1201-5. DOI: 10.1007/s10096-015-2348-3. View

17.

Villena J, Medina M, Vintini E, Alvarez S . Stimulation of respiratory immunity by oral administration of Lactococcus lactis. Can J Microbiol. 2008; 54(8):630-8. DOI: 10.1139/w08-052. View

18.

Moroti C, Souza Magri L, Costa M, Cavallini D, Sivieri K . Effect of the consumption of a new symbiotic shake on glycemia and cholesterol levels in elderly people with type 2 diabetes mellitus. Lipids Health Dis. 2012; 11:29. PMC: 3305430. DOI: 10.1186/1476-511X-11-29. View

19.

Thiennimitr P, Yasom S, Tunapong W, Chunchai T, Wanchai K, Pongchaidecha A . Lactobacillus paracasei HII01, xylooligosaccharides, and synbiotics reduce gut disturbance in obese rats. Nutrition. 2018; 54:40-47. DOI: 10.1016/j.nut.2018.03.005. View

20.

Creely S, McTernan P, Kusminski C, Fisher F, da Silva N, Khanolkar M . Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2006; 292(3):E740-7. DOI: 10.1152/ajpendo.00302.2006. View